Considering the leading role of hepatic lipid metabolism in the pathogenesis of MS [30–32], it is tempting to speculate that changes in the SCD1 expression in the liver might significantly alter the hepatic lipid metabolism aggravating the systemic metabolic derangement observed in patients with MS. This evidence concerns the gene SCD and myeloid sarcoma.